Workplace Intervention Including Exercise and Nutrition in Obese Office Workers

May 22, 2026 updated by: Konstantina Karatrantou, University of Thessaly

A Combined Workplace Intervention Including Exercise and Nutrition for Health Promotion in Obese Office Workers: a Randomized Controlled Study

The main objective of this study is to investigate the efficacy of a 6-month workplace combined (exercise and nutrition) intervention in obese office workers, using a randomized controlled study. An additional objective of this study is to evaluate the individual responses per participant following the program.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Greece
    • Greece
      • Trikala, Greece, Greece, 42100
        • Department of Physical Education and Sports Science, University of Thessaly

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sedentary work at least 8 h per day in the office
  • BMI value ≥ 30 kg/m2
  • No chronic diseases (physical or mental)
  • No use of any medication
  • No injuries (in lower or upper body) in the last 6 months
  • No participation in organized exercise programs or nutrition intervention during the last 6 months.

Exclusion Criteria: Participants who do not meet the above criteria will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention group
The IG will participate in a daily supervised 6-month workplace program (during working hours) including: a. exercise (flexibility, balance, strength, aerobic), and b. counseling and educational activities for healthy diet and hydration.
Other: Workplace combined (exercise and nutrition) intervention
The IG will participate in a supervised 6-month combined intervention program (exercise and nutrition), which will take place inside the workplace settings during working hours. In more detail, the IG will participate, every working day (5 days/week), in a 6-month supervised combined chair-based exercise program (120 training sessions; 25-40 min/day), including chair based seated and chair-assisted standing exercises to improve flexibility, balance, strength and aerobic capacity. Except exercise, the intervention program consisted of weekly counseling and educational activities in healthy diet and proper hydration using presentations, leaflets, individual and group sessions with nutritionist, use of applications for proper hydration, use of goal-setting cards for healthy options
No Intervention: Control group
The CG did not participate in any intervention.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Body fat
Time Frame: Baseline and 6 months
Body fat (BF): BF% will be assessed using the bioelectrical impedance method (Maltron 900).
Baseline and 6 months
Body circumferences
Time Frame: Baseline and 6 months
The waist and hip circumferences will be measured using an ergonomic circumference measuring tape (Seca 201).
Baseline and 6 months
Blood pressure
Time Frame: Baseline and 6 months
Systolic and diastolic blood pressure will be measured, using an electronic upper arm blood pressure monitor (A&D-UA-851).
Baseline and 6 months
Respiratory function
Time Frame: Baseline and 6 months
Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) will be measured, using a portable spirometer (Micro, Medical, Micro).
Baseline and 6 months
Lipidemic profile
Time Frame: Baseline and 6 months
A blood sample will be obtained after overnight fasting (12 h), as previously described [37]. Total cholesterol, high-density lipoprotein (HDL) and triglycerides will be determined using a biochemical analyzer (Clinical Chemistry Analyzer Z 1145; Zafiropoulos Diagnostica S.A., Koropi, Greece), and low-density lipoprotein (LDL) will be calculated using the Friedewald equation.
Baseline and 6 months
Lower body flexibility:
Time Frame: Baseline and 6 months
The sit-and-reach test will be performed using a Flex-Tester box (Novel Products Inc., Rockton, IL, USA).
Baseline and 6 months
Static balance
Time Frame: Baseline and 6 months
The single-limb stance test (with eyes opened) was performed, as previously described by Rinne et al.
Baseline and 6 months
Dynamic balance:
Time Frame: Baseline and 6 months
The timed up-and-go test was performed, as previously described by Rikli and Jones.
Baseline and 6 months
Handgrip strength
Time Frame: Baseline and 6 months
Maximal isometric handgrip strength will be assessed using a portable hydraulic dynamometer (Jamar 5030J1, Horsham, USA).
Baseline and 6 months
Aerobic capacity:
Time Frame: Baseline and 6 months
The YMCA 3 min step test was used, which will be performed following the metronome cadence (96 beats per minute; 4 steps per cycle). The participants' HR will be measured 1 min following the termination of the step test.
Baseline and 6 months
Adherence to the Mediterranean diet
Time Frame: Baseline and 6 months
The adherence to the Mediterranean diet will be assessed before and after the 6-month period using the specific Mediterranean Diet Score (range of total score: 0-55) [34-35]. The MedDietScore measures the weekly consumption of the following 9 food groups: non-refined cereals (whole grain bread and pasta, brown rice, etc), fruit, vegetables, legumes, potatoes, fish, red meat and products, poultry, full fat dairy products (like cheese, yoghurt, milk), as well as olive oil and alcohol intake [35].
Baseline and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Thessaly

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Konstantina Karatrantou, University of Thessaly
  • Principal Investigator: Vassilis Gerodimos, University of Thessaly

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 30, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 30, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 28, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 28, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 22, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 1760

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings